Clinical Trial News Archive
Get news by email or subscribe to our news feeds.
News Archive for September 2009
September 1, 2009
- Novavax Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine Candidate
- ACADIA Pharmaceuticals Announces Results from Phase III Trial of Pimavanserin in Parkinson's Disease Psychosis
- TransPharma Announces Successful Completion of Phase 2 Trial of ViaDerm-hPTH (1-34) in Postmenopausal Women with Osteoporosis
- New Large-Scale, Global Study Provides Additional Information About an Intensified Dose-Regimen of Plavix in Acute Coronary Syndrome Patients Undergoing Angioplasty
- Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients
- Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes
September 2, 2009
- Crestor Reduced Risk of Cardiovascular Events in Elderly Patients in New Analysis of Jupiter
- Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
- Acceleron Pharma's ACE-031 Increases Lean Body Mass in Phase 1 Single Dose Clinical Trial
- New Results In Angina Patients: Fewer Heart Attacks With Procoralan (Ivabradine)
September 3, 2009
- Enabling Capabilities of Inovio Biomedical's Electroporation Delivery Technology with SIV DNA Vaccine Confirmed in Collaborative Study With National Cancer Institute
- HPV Vaccine Could Prevent Breast Cancer: Australian Research
- Novartis MF59 Adjuvanted Cell Culture-Based Vaccine Shows Strong Immune Response In A(H1N1) Clinical Trials
- Curis Announces GDC-0449 Phase I Clinical Data Published in New England Journal of Medicine
September 4, 2009
- Novel Evidence-Based Systemic Lupus Erythematosus (SLE) Responder Index Described in Peer Reviewed Publication as Potentially Significant Advance in Lupus Drug Development
- Array BioPharma Announces Top-Line Results from Rheumatoid Arthritis Phase 2 Trial
- NovaDel Article Published in Headache: The Journal of Head and Face Pain
- PharmAthene Presents Data for Valortim Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference
- Large Thighs Protect Against Heart Disease and Early Death
- Gene Signal and Collaborators Publish GS-101 Clinical Data Suggesting Safe and Effective Inhibition of Abnormal Ophthalmic Blood Vessel Growth
- Promising Results of Drug Trial Could Herald a Replacement for Popular Blood Thinner
- LIVALO Demonstrates Sustained, Long-Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
September 6, 2009
- Study Shows Livalo is not Affected by Co-Administration of Itraconazole
- Nitec Pharma Reports Positive and Highly Significant Phase III Results From Capra-2 Study of Lodotra in RA
- Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrine's Cotara for Treatment of Brain Cancer
September 7, 2009
September 8, 2009
- XenoPort Reports Preliminary Results From a Safety and Tolerability Trial of Arbaclofen Placarbil in Patients With Acute Back Spasms
- Opexa Reports Additional Favorable Data with Tovaxin for Multiple Sclerosis
- Will the FDA Ban Hydroquinone in Pigment Control Products?
- New Teva Data Highlights Advances in MS Treatment Research
- Emisphere Technologies Announces Publication in Clinical Pharmacology and Therapeutics of Encouraging Data from an Independent Clinical Study of an Oral Eligen-GLP-1 Formulation on Glucose Homeostasis
- NanoBio's Vaccine Adjuvant Platform Demonstrates Robust Immunity and Cross Protection Against Influenza
- Can-Fite Announces Positive Results from its Psoriasis Phase II Trial with CF101
- Osiris Therapeutics Announces Preliminary Results for Prochymal Phase III GvHD Trials
September 9, 2009
- VIVUS to Host Conference Call and Webcast Discussion of Qnexa Phase 3 Results
- Vivus Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
- Cytheris to Present Interim Data from INSPIRE HIV Multicenter Study in Oral Late Breaker at ICAAC
- Ore Pharmaceuticals Announces Upcoming Publication of Research Study on ORE1001
- Affymax Provides Phase 3 Program Update for Investigational Drug, Hematide, to Treat Anemia in Chronic Renal Failure
- Largest comparative hepatitis C study confirms treatment effectiveness...
September 10, 2009
- Acorda Therapeutics Announces Interim Analysis of Two-Year Efficacy and Safety Data from Phase 3 Fampridine-SR Extension Study
- Reliability and Validity of Dyax's Novel Patient Reported Outcome Measures (PROs) Affirmed in Published Study
- Dexamethasone-Based Therapy Shows Improvement In Survival For Children With Acute Lymphoblastic Leukaemia
- New research indicates 95% of patients are in moderate to severe chronic pain despite one year of treatment
- QuatRx Announces Positive Results of Second Pivotal Phase 3 Clinical Study for Ophena (Ospemifene Tablets) in Treatment of Postmenopausal Vaginal Atrophy
- Protox announces positive 12 month Phase 2 BPH results
- MAP Pharmaceuticals' Analysis of Positive Phase 3 Levadex Data To Be Presented in Late-Breaking Session at 14th Congress of the International Headache Society
- Mpex Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results with Aeroquin(R) (MP-376) Treatment in Cystic Fibrosis Patients
- Virus Responsible For Deadly Brain Disease Found In MS Patients Treated With Natalizumab
- Zelrix, a Novel Transdermal Patch for Migraine, Found to Provide Rapid, Consistent, and Sustained Relief for Migraine Sufferers in Phase III Trial
- Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009
- Acceleron Pharma's ACE-031 Increases Lean Body Mass in Phase 1 Single Dose Clinical Trial
- Key Data Related to Plexxikon's Lead Oncology Program PLX4032 to Be Presented at ECCO15 / ESMO34 2009 Conference
September 11, 2009
- Variation Biotechnologies to Present Positive Influenza Vaccine Data at the 49th Annual ICAAC Meeting
- New WHO Data Underscores Global Threat of the World's Leading Child Killer
- Encouraging Phase II Results With Teriflunomide In Patients With Relapsing Multiple Sclerosis
- Results from IMPROVE Study Show MRI Benefits of Rebif Seen Early in Relapsing-Remitting Multiple Sclerosis Treatment and Sustained Over Time
- Data Supporting Unique Efficacy of Tysabri Presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- New Data From CLARITY Study on Disease Activity in MS Patients Who Received Cladribine Tablets Presented at 25th ECTRIMS Congress
- Fewer Injection Site Reactions in Patients Using Avonex Versus Sub-cutaneous Interferon and Glatiramer Acetate for the Treatment of Multiple Sclerosis
- Laquinimod Immunomodulatory Action Confers Both Neuroprotective and Anti-Inflammatory Properties
- New Data Show Patients With Chronic Low Back Pain Maintained Pain Reduction on Cymbalta
- Genzyme's Alemtuzumab for Multiple Sclerosis Shows Durable Treatment Benefit in Review of Four-Year Phase 2 Trial Data
- Statement by Dr. Anthony Fauci, Director, National Institute of Allergy and Infections Diseases, NIH, Regarding Early Results from Clinical Trials of 2009 H1N1 Influenza Vaccines in Healthy Adults
- Instanyl (intranasal fentanyl spray) Sets New Standard in Management of Breakthrough Cancer Pain
- Data to be Presented on Multiple Targacept NNR Therapeutics at Society for Neuroscience Satellite Symposium
- Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009
September 14, 2009
- Variation Biotechnologies Flu Vaccine Provides Robust Immune Response, Broad Protection against H1N1 Influenza Strain
- Aradigm Presents Data Demonstrating Significant Antibacterial Concentrations and Effects in Non-Cystic Fibrosis Bronchiectasis Patients Following Administration of its Once-Daily Inhaled Liposomal Ciprofloxacin
- Concert Pharmaceuticals Presents Clinical Results Demonstrating Reduced Drug-Drug Interactions with a Deuterium-Modified Compound
- Pandemic (H1N1) 2009 Influenza Update: Initial Results from First Clinical Trial of GSK?s H1N1 Adjuvanted Vaccine
- Altair Therapeutics Reports Successful Phase I Study of Inhaled AIR645
- Kenta Biotech Reports Phase IIa Data with Lead Candidate Panobacumab in Hospital-Acquired Pneumonia
- ExonHit Presents Promising First Patient Results for EHT 0202, Its Alzheimer's Candidate Drug
- Salix Pharmaceuticals Announces Statistically Significant Results for Both the Primary and Key Secondary Analyses Of Rifaximin in the Treatment of Non-Constipation Irritable Bowel Syndrome in Two Phase 3 Trials (Target 1 and Target 2)
- New, Long-Term Data for Odanacatib, Merck's Investigational Cat K Inhibitor, Showed Positive Results in Treating Osteoporosis
September 15, 2009
- Acorda Therapeutics Announces Data on Retention Rates and Safety from Two Phase 3 Fampridine-SR Extension Studies
- Schering-Plough Reports Long-Term Vicriviroc Data From Phase II Open-Label Extension Study in Treatment-Experienced HIV-Infected Patients
- Argenta Discovery Publishes Positive Data From a Phase II Proof of Concept Trial with Co-Administration of Inhaled ADC4022 Plus Budesonide Study in COPD
- Novartis investigational bronchodilator QAB149 improves lung function and reduces breathlessness compared to tiotropium in patients with COPD
- New efficacy data on Basilea's novel antibiotic against multi-resistant Gram-negative bacteria presented at ICAAC
- Wyeth Presents Data from Five-Year Vertebral Fracture Prevention Study with Bazedoxifene
- Kamada Presents Data on Inhaled Alpha-1 Antitrypsin in Cystic Fibrosis Patients at the European Respiratory Society Meeting 2009, Vienna
- Merck's ISENTRESS (raltegravir) Tablets Studied in Comparison to Efavirenz in Combination Therapy Through 96 Weeks in HIV-1 Treatment-Naïve Patients
- Pivotal Data Demonstrating Efficacy of Darusentan in Treating Resistant Hypertension Published in The Lancet
- Ipsen: Encouraging Preliminary New Data Available for the Treatment of Short Stature Children with Low IGF-1 Levels
- Encouraging Preliminary New Data Available for the Treatment Of Short Stature Children With Low IGF-1 Levels
- QVA149 Phase II data presented at the European Respiratory Society annual meeting
- Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting
- Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress
- BioAlliance Pharma Makes Four Presentations at the 49th ICAAC Meeting Including Three Phase III Study Results with miconazole Lauriad and One with Its Integrase Inhibitor
- Cytheris Announces Interim Data from INSPIRE Study Showing Interleukin-7 (CYT107) Induces Dose-Dependent and Sustained Increase of CD4 T Cells in Chronic HIV-Infected Patients
- Medivir Has Presented Lipsovir at the Ongoing 49th ICAAC Meeting in San Francisco, USA
- Achaogen Announces ACHN-490 Clinical Data at the 49th Annual ICAAC Meeting
- NanoBio Presents Key Data on the Use of Nanoemulsions to Treat Burn Wound Infections
September 16, 2009
- Potential Once-weekly Asthma Treatment Found Safe, Well-Tolerated in Study
- QVA149 Phase II Data Presented at the European Respiratory Society Annual Meeting
- Schering-Plough Reports Data From Saphris (asenapine) Long-Term Schizophrenia Relapse Prevention Study
- Enobia Announces Positive Clinical Results With ENB-0040, a Bone Targeted Enzyme Replacement Therapy for Hypophosphatasia
- ExonHit presents promising first patient results for EHT 0202, its Alzheimer's candidate drug
- Detailed Data From Vical's TransVax CMV Vaccine Phase 2 Trial Presented in Late-Breaker Session at ICAAC
- Treatment with Insulin or Metformin Does Not Reduce Inflammatory Biomarkers for Patients With Diabetes
- Medivir Presented Its Cathepsin K Program at the Ongoing 31st ASBMR Meeting in Denver, USA
September 17, 2009
- Bioheart Inc. Announces Positive Results in the MARVEL Phase II/III Clinical Trial
- TYSABRI Data: ECTRIMS (European Committee for the Treatment and Research in Multiple Sclerosis)
- 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkin's Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherapy
- Positive Phase IIb Results for GSK1838262 (XP13512) Reported for Neuropathic Pain Associated with Post-Herpetic Neuralgia
- Anemic Patients With MDS Gain Long-Term Benefits From Erythropoietin and Myeloid Growth Factor Hormones
- Phase III Study Showed Patients Lived Longer Without Low-Grade Lymphoma Progressing When Rituxan Was Used First-Line for Maintenance
- STALLERGENES: Immunotherapy Tablet Containing Recombinant Allergen (rBet v 1) of Birch Pollen: Positive Results for a Phase IIb/III Trial
September 18, 2009
- Algeta to present new clinical data from three phase II trials with Alpharadin at ECCO 15 - 34th ESMO Congress
- Study shows MabThera maintenance treatment delays disease progression in patients with incurable lymphoma
- Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
- Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 - ESMO 34 Congress
- Pfizer To Present Research On Established Therapies And New Approaches To Cancer Treatment Using Investigational Agents
September 19, 2009
- Study Demonstrates That QVAR is More Cost-Effective Than Other Inhaled Corticosteroid (ICS) Asthma Therapy Options
- Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
- First Human Data on Deuterlium-Modified Drugs This Week
- Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer
September 21, 2009
September 22, 2009
- Dynavax Announces HEPLISAV Data to Be Presented at IDSA Medical Conference
- Survival Benefit Maintained in Long Term Follow-up of IES with Pfizer's AROMASIN (Exemestane Tablets)
- Provectus Completes Treatment of All Patients in Phase 2 Trial of PV-10 for Metastatic Melanoma
- Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases
- Impax Pharmaceuticals Reports Positive Results of Phase II Trial of IPX066, a Novel Formulation of Carbidopa-Levodopa for Parkinson's Disease
- Incyte Announces Positive Top-Line Phase IIb Results for Topical INCB18424 in Psoriasis
- Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients
- Avastin could play an important role in improving the daily lives of patients with the most aggressive form of brain cancer
- Micromet Reports Interim Data from Phase 1 Study of BiTE Antibody MT110 for the Treatment of Solid Tumors
- 'Headache' Publication Describes Potential Mechanistic Rationale for Levadex Favorable Adverse Event Profile
- New results from ADVANCE trial at International Diabetes Federation (IDF) Congress 2009
- New phase II data presented at ECCO 15 - 34th ESMO Congress reinforces exciting potential of Algeta's Alpharadin as a new treatment for bone metastases in cancer patients
- Important data for NicOx' naproxcinod published in the American Journal of Cardiology
- Abbott's XIENCE V Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
September 23, 2009
- Idera Pharmaceuticals Presents Interim Data from Phase 1b Clinical Trial of IMO-2055 in Combination with Tarceva and Avastin in Non-Small Cell Lung Cancer
- Plexxikon Announces Encouraging Data from Phase 1 Extension Study of PLX4032 Showing Objective Responses in Metastatic Melanoma Patients
- Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival in Patients With Advanced Breast Cancer in Phase 2 Study
- Data Presented from Two Phase 3 Erbitux Studies in First-Line Metastatic Colorectal Cancer Patients at Joint 15th European Cancer Organisation and 34th European Society for Medical Oncology Multidisciplinary Congress
- From inoperable disease to potentially life saving surgery - new Avastin data gives hope to colorectal cancer patients with liver metastases
- Initial COIN Study Results Presented at European Oncology Congress
- AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS-112 in Cancer
- Lux Biosciences Reports Phase 1 Safety Results and Open Label Efficacy Results for LX214, a Potential Best-in-Class Treatment for Dry Eye
- Elixir Medical Corporation Announces Positive First-In-Man Results for Three Drug Eluting Coronary Stent Systems with Durable and Bioabsorbable Polymers
- SPIRIT IV Results Reaffirm Strong Performance of Boston Scientific PROMUS and TAXUS Express Stents
- Abbott's XIENCE V Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS(R) Liberte in Investigator-Initiated COMPARE Trial
- Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
- PAREXEL Consulting Releases New Study Data on Drug Development Timelines in Safety First Era
- TAXUS Liberte Stent Continues to Demonstrate Significant Improvements Over TAXUS Express Stent in Small Vessels and Long Lesions
- NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
- Vectibix in Combination With Chemotherapy Significantly Improves Progression-Free Survival in Second-Line Metastatic Colorectal Cancer
- Denosumab Demonstrates Superiority Over Zometa in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients
- Results of ADAGIO Study with AZILECT in Parkinson's Disease Published in New England Journal of Medicine
September 24, 2009
- Two Phase Iii Studies Confirm Efficacy Of Iressa In EGFR MUTATION+ NSCLC
- Results of ADAGIO study with Azilect in Parkinson's disease published in The New England Journal of Medicine
- IAVI Statement on Results of Phase III ALVAC-AIDSVAX Trial in Thailand
- Alkermes Announces Amylin and Lilly Will Present More than 20 Studies for Exenatide at EASD 2009
- Genzyme's Campath Meets Primary Endpoint in Phase 3 Combination Therapy Trial for Chronic Lymphocytic Leukemia
- Interim Results From Phase Iii Trist Study Of Trovax In Renal Cancer
- Ticagrelor Reduced Cardiovascular Deaths and Heart Attacks in ACS Patients Undergoing Heart Procedures: New Data from PLATO Trial
- Vertex Pharmaceuticals Announces Publication of Telaprevir Abstracts for Presentation at the 60th AASLD Meeting
- NEVO? Sirolimus-Eluting Coronary Stent Associated with Significantly Less Chest Pain at Six Months Than Taxus Liberte Stent
September 25, 2009
- Vectibix in Combination With Chemotherapy Significantly Improves Progression-Free Survival in First-Line Metastatic Colorectal Cancer
- Active Biotech's Prostate Cancer Project TASQ Featured in British Journal of Cancer
- Idera Pharmaceuticals Presents Final Data from Phase 2 Clinical Trial of IMO-2055 Monotherapy in Renal Cell Carcinoma
- Prime-Boost Vaccine Study Shows Modest Effect in Preventing HIV
- Angiomax Reduced Cardiac Mortality by 41%; Reduced Overall Mortality by 25% in Severe Heart Attack Patients Following Angioplasty
September 26, 2009
- Chelsea Therapeutics Reports Preliminary Phase III Data of Droxidopa for Treatment of Symptomatic Neurogenic Orthostatic Hypotension
- ECCO/ESMO Highlights Plexxikon Melanoma Data Given 70% Response Rate
September 27, 2009
September 28, 2009
September 29, 2009
- Alimera Reports Safety and Efficacy Results From the 18-Month Interim Readout of the Human PK Iluvien(R) Study
- Hythiam Announces First Peer-Reviewed Publication of Statistically Significant Results from Randomized, Double-Blind, Placebo-Controlled Study
- Updated Single Agent Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Carcinoma Reported at the Eighth International Kidney Cancer Symposium
- New Data Suggest that Gelnique (oxybutynin chloride) gel 10% Does Not Impact Cognition among Healthy Older Adults
- pSivida Reports Safety and Efficacy Results from 18-Month Interim Readout of Human PK Iluvien Study
- Acrux Announces Successful AXIRON Phase III Trial Results
- Sanofi-aventis launches major insulin research program in partnership with the international scientific community
